- Broadens institutional and retail investor foundation throughout EU and allows access to extra capital marketplaces
- No linked capital boosting – trade of present securities with trade quantity to enhance on ASX
- On-the-floor investor relations agency to further help meant research plans in EU
SYDNEY, Australia, Feb. 24, 2021 (World NEWSWIRE) — Recce Prescribed drugs Ltd (ASX:RCE) (Firm), the Corporation acquiring new courses of synthetic anti-infectives is happy to announce it has commenced the software system to dual listing its stock on the Frankfurt Inventory Exhange (FSE).
“Dual-listing on FSE enables Recce to broaden its exposure to European buyers,” reported Dr. John Prendergast, Non-Government Chairman of Recce Prescribed drugs Ltd. “The Enterprise considers that it fulfills the needs necessary to twin-list on FSE and will provide updates on its software development.”
Twin listing on the FSE will see the Enterprise maximize publicity to a significant foundation of retail and institutional investors in the European Union (EU) as a result of German Trading Exchanges (Frankfurt, Tradegate, Berlin, Stuttgart). The Frankfurt Stock Trade is the third most significant in Europe and tenth major in the environment.
Recce Pharmaceuticals has appointed Deutsche Gesellschaft Für Wertpapieranalyse GMBH (DGWA) as its investor and company relations advisor in Europe. DGWA will aid engagement with future buyers in the German talking DACH area (Germany, Austria and Switzerland) although driving recognition of Recce’s novel artificial anti-infective compounds.
Mr. Stefan Müller, the CEO of DGWA extra, “We are psyched to help Recce in engagement with European traders and opportunities to broaden its infectious disease plans.”
The Corporation will offer the industry further updates on its listing process on materials developments, with expectation the process will be accomplished in forthcoming months.
About Recce Pharmaceuticals Ltd
Recce Prescribed drugs Ltd (ASX: RCE) is groundbreaking the improvement and commercialization of New Lessons of Artificial Anti-Infectives intended to deal with the urgent world wide wellness challenges of antibiotic resistant superbugs and rising viral pathogens.
Recce’s anti-infective pipeline is exclusive and comprised of broad-spectrum artificial polymer antibiotics RECCE® 327, RECCE® 435, and RECCE® 529 for viral bacterial infections with one of a kind mechanisms of motion in opposition to hyper-mutation on bacteria and viruses, respectively.
Patented lead prospect RECCE® 327 has been designed for the treatment of blood infections and sepsis derived from E. coli and S. aureus germs – including their superbug types. Recce’s new antibiotic compound, RECCE® 435, has been formulated for oral use.
The Food and drug administration has awarded RECCE® 327 Experienced Infectious Disorder Products designation below the Creating Antibiotic Initiatives Now (Gain) Act – labelling it for Rapidly Observe Designation, additionally 10 many years of industry exclusivity post approval.
Recce wholly owns its automated producing, all set to help very first-in-human clinical trials. Recce’s anti-infective pipeline seeks to exploit the special abilities of RECCE® technologies concentrating on synergistic, unmet health-related wants.
Company Make contact with
Recce Prescription drugs Ltd
+61 (02) 8075 4585
Media and Trader Relations (AU)
+61 (02) 9267 4511
Media and Investor Relations (United states)
Meredith Sosulski, Ph.D.
+1 929 469 3851